BRPI0206433B8 - composto, composição farmacêutica, e, uso de um composto - Google Patents
composto, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BRPI0206433B8 BRPI0206433B8 BRPI0206433A BRPI0206433B8 BR PI0206433 B8 BRPI0206433 B8 BR PI0206433B8 BR PI0206433 A BRPI0206433 A BR PI0206433A BR PI0206433 B8 BRPI0206433 B8 BR PI0206433B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- preparing
- compounds
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0100889.5A GB0100889D0 (en) | 2001-01-12 | 2001-01-12 | Compounds |
GB0100889.5 | 2001-01-12 | ||
PCT/GB2002/000106 WO2002055498A1 (en) | 2001-01-12 | 2002-01-11 | Pharmaceutically active piperidine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0206433A BR0206433A (pt) | 2003-12-30 |
BRPI0206433B1 BRPI0206433B1 (pt) | 2020-01-07 |
BRPI0206433B8 true BRPI0206433B8 (pt) | 2021-05-25 |
Family
ID=9906757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0206433-2 BRPI0206433B8 (pt) | 2001-01-12 | 2002-01-11 | composto, composição farmacêutica, e, uso de um composto |
Country Status (19)
Country | Link |
---|---|
US (3) | US20040097551A1 (pt) |
EP (1) | EP1362031B1 (pt) |
JP (1) | JP4313572B2 (pt) |
KR (1) | KR100879651B1 (pt) |
CN (1) | CN1267420C (pt) |
AT (1) | ATE389635T1 (pt) |
AU (1) | AU2002219363B2 (pt) |
BR (1) | BRPI0206433B8 (pt) |
CA (1) | CA2433675C (pt) |
DE (1) | DE60225671T2 (pt) |
ES (1) | ES2304439T3 (pt) |
GB (1) | GB0100889D0 (pt) |
HU (1) | HU229428B1 (pt) |
IL (1) | IL156873A0 (pt) |
MX (1) | MXPA03006185A (pt) |
PT (1) | PT1362031E (pt) |
RU (1) | RU2279425C2 (pt) |
WO (1) | WO2002055498A1 (pt) |
ZA (1) | ZA200305118B (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
ATE339203T1 (de) * | 2002-03-13 | 2006-10-15 | Unither Pharmaceuticals Inc | Nicht hormonale verfarhen zur männlicher verhütung |
CA2492410C (en) | 2002-07-17 | 2011-09-13 | Oxford Glycosciences (Uk) Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
AU2003246942B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
GB0313678D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
JP2007509925A (ja) * | 2003-10-29 | 2007-04-19 | マクロジーメ ビー.ブイ. | デオキシノジリマイシン誘導体又はその薬学的塩の使用 |
EP1528056A1 (en) * | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
GB0400812D0 (en) * | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
US20060025449A1 (en) * | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
US20070248591A1 (en) * | 2004-09-08 | 2007-10-25 | Takeda Pharmaceutical Company Limited | Preventive/Therapeutic Drug for Arteriosclerosis |
EP1811991B1 (en) | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
DK2032134T3 (en) | 2006-05-09 | 2015-09-28 | Genzyme Corp | Processes for the treatment of fatty liver disease which includes inhibition of glucosphingolipidsyntese |
JP5241709B2 (ja) * | 2006-05-24 | 2013-07-17 | ユナイテッド セラピューティクス コーポレーション | デオキシノジリマイシンおよびd−アラビニトールのアナログおよび使用方法 |
GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
US8097728B2 (en) * | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
EP2594565B1 (en) | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
JP5896601B2 (ja) * | 2007-10-05 | 2016-03-30 | ジェンザイム コーポレーション | セラミド誘導体を用いる多発性嚢胞腎疾患の治療方法 |
WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
RU2578947C2 (ru) | 2008-10-03 | 2016-03-27 | Джензайм Корпорейшн | Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа |
WO2010075010A2 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
WO2010096764A1 (en) * | 2009-02-23 | 2010-08-26 | United Therapeutics Corporation | Iminosugars and methods of treating viral diseases |
ES2562635T3 (es) * | 2009-02-24 | 2016-03-07 | United Therapeutics Corporation | Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus |
CN102639133B (zh) * | 2009-06-12 | 2015-03-11 | 联合治疗公司 | 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法 |
DK2473482T3 (en) * | 2009-09-04 | 2014-05-12 | United Therapeutics Corp | Methods of treating orthomyxoviral infections |
CN105748476A (zh) * | 2009-09-04 | 2016-07-13 | 联合治疗公司 | 亚氨基糖以及治疗丝状病毒性疾病的方法 |
JP5575246B2 (ja) * | 2009-09-04 | 2014-08-20 | ユナイテッド セラピューティクス コーポレイション | ポックスウイルス感染の治療方法 |
JP2013512945A (ja) * | 2009-12-07 | 2013-04-18 | ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード | 破骨細胞生成および/または破骨細胞活性化の阻害における使用のためのn置換デオキシノジリマイシン化合物 |
ES2371398B1 (es) * | 2010-06-04 | 2013-05-20 | Bioglane, S.L.N.E. | Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales. |
EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
EP2785335B8 (en) | 2011-11-29 | 2017-08-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of darier disease |
KR20150128899A (ko) * | 2013-03-15 | 2015-11-18 | 유니터 바이롤로지, 엘엘씨 | 항박테리아 화합물 |
CA2911149A1 (en) * | 2013-05-02 | 2014-11-06 | The Chancellor, Masters And Scholars Of The University Of Oxford | Glycolipid inhibition using iminosugars |
CN110799497A (zh) | 2017-06-01 | 2020-02-14 | 爱杜西亚药品有限公司 | N-丁基脱氧半乳糖野尻霉素的结晶型 |
WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
JP2022531933A (ja) * | 2019-05-10 | 2022-07-12 | アレクトス セラピューティックス インコーポレイテッド | 非リソソームグルコシルセラミダーゼ阻害剤及びその使用 |
WO2021224865A1 (en) * | 2020-05-07 | 2021-11-11 | Alectos Therapeutics Inc. | Non-lysosomal glucosylceramidase inhibitors and uses thereof |
EP4201403A1 (en) | 2021-12-21 | 2023-06-28 | Som Innovation Biotech, S.L. | Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
DE3007078A1 (de) | 1980-02-26 | 1981-09-10 | Bayer Ag, 5090 Leverkusen | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung |
DE3024901A1 (de) | 1980-07-01 | 1982-01-28 | Bayer Ag, 5090 Leverkusen | Herbizide mittel auf basis von piperidin-derivaten |
DE3247615A1 (de) | 1982-12-23 | 1984-07-05 | Hoechst Ag, 6230 Frankfurt | Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
DE3737523A1 (de) | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
US5003072A (en) | 1988-11-03 | 1991-03-26 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
JPH02306962A (ja) | 1989-05-19 | 1990-12-20 | Meiji Seika Kaisha Ltd | 新規n―置換―1―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤 |
JPH0324057A (ja) | 1989-06-22 | 1991-02-01 | Tosoh Corp | ポリヒドロキシピペリジン類及びその製造法 |
EP0491041A4 (en) | 1989-09-07 | 1993-03-03 | Nippon Shinyaku Company, Limited | Antiviral drug |
WO1992000277A1 (fr) | 1990-06-29 | 1992-01-09 | Nippon Shinyaku Co., Ltd. | Derive de piperidine |
US5276120A (en) | 1991-05-30 | 1994-01-04 | The Scripps Research Institute | Process for forming omega-deuxy-azasugars |
WO1994025603A1 (de) | 1993-05-05 | 1994-11-10 | Boehringer Mannheim Gmbh | Cholesterinoxidase aus brevibacterium sterolicum |
US6291657B1 (en) * | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
EP0912179B1 (en) * | 1996-07-15 | 2006-04-12 | MacroZyme DNM B.V. | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
WO1998050359A1 (en) | 1997-05-06 | 1998-11-12 | Novo Nordisk A/S | Novel heterocyclic compounds |
US6426198B1 (en) | 1997-07-03 | 2002-07-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Genes for Niemann-Pick type C disease |
EP1030839B1 (en) | 1997-11-10 | 2004-02-04 | G.D. SEARLE & CO. | Use of alkylated iminosugars to treat multidrug resistance |
US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
WO2000056334A1 (en) | 1999-03-19 | 2000-09-28 | The Trustees Of Boston College | Use of imino sugars for anti-tumor therapy |
GB9909064D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
DE60001745T2 (de) | 1999-07-26 | 2004-03-04 | G.D. Searle & Co., Chicago | Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten |
US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
JP2003506406A (ja) * | 1999-08-10 | 2003-02-18 | ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード | 長鎖n−アルキル化合物およびそのオキサ誘導体 |
ATE339203T1 (de) | 2002-03-13 | 2006-10-15 | Unither Pharmaceuticals Inc | Nicht hormonale verfarhen zur männlicher verhütung |
CA2492410C (en) | 2002-07-17 | 2011-09-13 | Oxford Glycosciences (Uk) Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
AU2003246942B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
GB0313678D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
-
2001
- 2001-01-12 GB GBGB0100889.5A patent/GB0100889D0/en not_active Ceased
-
2002
- 2002-01-11 MX MXPA03006185A patent/MXPA03006185A/es active IP Right Grant
- 2002-01-11 BR BR0206433-2 patent/BRPI0206433B8/pt not_active IP Right Cessation
- 2002-01-11 DE DE60225671T patent/DE60225671T2/de not_active Expired - Lifetime
- 2002-01-11 WO PCT/GB2002/000106 patent/WO2002055498A1/en active IP Right Grant
- 2002-01-11 PT PT02729458T patent/PT1362031E/pt unknown
- 2002-01-11 HU HU0303891A patent/HU229428B1/hu unknown
- 2002-01-11 KR KR1020037009309A patent/KR100879651B1/ko active IP Right Grant
- 2002-01-11 RU RU2003124756/04A patent/RU2279425C2/ru active
- 2002-01-11 EP EP02729458A patent/EP1362031B1/en not_active Expired - Lifetime
- 2002-01-11 CA CA2433675A patent/CA2433675C/en not_active Expired - Lifetime
- 2002-01-11 ES ES02729458T patent/ES2304439T3/es not_active Expired - Lifetime
- 2002-01-11 IL IL15687302A patent/IL156873A0/xx active IP Right Grant
- 2002-01-11 JP JP2002556170A patent/JP4313572B2/ja not_active Expired - Lifetime
- 2002-01-11 AT AT02729458T patent/ATE389635T1/de active
- 2002-01-11 CN CNB028062264A patent/CN1267420C/zh not_active Expired - Lifetime
- 2002-01-11 AU AU2002219363A patent/AU2002219363B2/en not_active Expired
-
2003
- 2003-07-01 ZA ZA200305118A patent/ZA200305118B/en unknown
- 2003-07-11 US US10/618,165 patent/US20040097551A1/en not_active Abandoned
-
2005
- 2005-08-03 US US11/196,153 patent/US8729099B2/en not_active Expired - Lifetime
-
2014
- 2014-04-07 US US14/246,879 patent/US9199935B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE389635T1 (de) | 2008-04-15 |
HUP0303891A2 (hu) | 2004-03-29 |
DE60225671T2 (de) | 2009-04-16 |
RU2003124756A (ru) | 2005-01-10 |
WO2002055498A1 (en) | 2002-07-18 |
US20140303208A1 (en) | 2014-10-09 |
EP1362031A1 (en) | 2003-11-19 |
US20040097551A1 (en) | 2004-05-20 |
KR20030081383A (ko) | 2003-10-17 |
ZA200305118B (en) | 2004-10-01 |
BRPI0206433B1 (pt) | 2020-01-07 |
DE60225671D1 (de) | 2008-04-30 |
EP1362031B1 (en) | 2008-03-19 |
CN1496351A (zh) | 2004-05-12 |
CA2433675A1 (en) | 2002-07-18 |
RU2279425C2 (ru) | 2006-07-10 |
HU229428B1 (en) | 2013-12-30 |
JP4313572B2 (ja) | 2009-08-12 |
MXPA03006185A (es) | 2004-12-03 |
KR100879651B1 (ko) | 2009-01-20 |
US9199935B2 (en) | 2015-12-01 |
IL156873A0 (en) | 2004-02-08 |
ES2304439T3 (es) | 2008-10-16 |
AU2002219363B2 (en) | 2007-11-01 |
GB0100889D0 (en) | 2001-02-21 |
BR0206433A (pt) | 2003-12-30 |
JP2004517869A (ja) | 2004-06-17 |
US8729099B2 (en) | 2014-05-20 |
US20060074107A1 (en) | 2006-04-06 |
CN1267420C (zh) | 2006-08-02 |
HUP0303891A3 (en) | 2010-01-28 |
PT1362031E (pt) | 2008-06-12 |
CA2433675C (en) | 2011-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0206433B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0506843A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
DK1206467T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
NO993996L (no) | N-heterosykliske derivater som NOS-inhibitorer | |
ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
BRPI0720525B8 (pt) | inibidores de mapk/erk quinase | |
BR0314113A (pt) | Derivados de amino propanol | |
UY27571A1 (es) | 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso | |
BRPI0510409A (pt) | heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase | |
BRPI0512986A (pt) | novos derivados de hidantoìna | |
BR0210464A (pt) | Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto | |
BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
DK1268471T3 (da) | N-heterocykliske derivater som NOS-inhibitorer | |
NO20061317L (no) | Imidazopyridinderivater som induserbare NO-syntaseinhibatorer | |
BRPI0508969A (pt) | compostos orgánicos | |
BRPI0517033A (pt) | novos derivados de hidantoìna como inibidores de metaloproteinase | |
BRPI0411308A8 (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
NO20061344L (no) | Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer | |
UY30356A1 (es) | Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos. | |
NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
SE0403085D0 (sv) | Novel componds | |
BRPI0108990B8 (pt) | processo para preparação de derivados de pirimidona com atividade antifungos | |
BRPI0415034A (pt) | derivados de aminopiridina como inibidores de não-sintase induzìveis | |
BR0308601A (pt) | inibidores de carboxipeptidase b de plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER Free format text: TRANSFERIDO DE: OXFORD GLYCOSCIENCES (UK) LIMITED |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B25C | Requirement related to requested transfer of rights |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870180063890 DE 24/07/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO ?ACTELION PHARMACEUTICALS LIMITED? E O NOME DA EMPRESA CEDENTE ?ACTELION PHARMACEUTICALS LTD?. Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITH OF OXFORD (GB) ; ACTELION PHARMACEUTICALS LIMITED (CH) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870180063890 DE 24/07/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO ?ACTELION PHARMACEUTICALS LIMITED? E O NOME DA EMPRESA CEDENTE ?ACTELION PHARMACEUTICALS LTD?. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER Free format text: ANULADA A PUBLICACAO CODIGO 25.3 NA RPI NO 2487 DE 04/09/2018 POR TER SIDO INDEVIDA. |
|
B25A | Requested transfer of rights approved |
Owner name: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVER |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/01/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 11/01/2022 |